Ceftazidime-Avibactam: Composition, Action, Resistance, and Interactions

Ceftazidime-avibactam is a combination antibiotic that pairs a well-established cephalosporin (ceftazidime) with a newer beta-lactamase inhibitor (avibactam) to treat serious gram-negative infections that have become resistant to many other drugs. Approved for use in adults and, more recently, in children, it has become one of the most important weapons against carbapenem-resistant bacteria, a category of infections that was previously treatable only with older, more toxic drugs. The combination’s composition, its dual mechanism, the ways bacteria can evade it, and the practical considerations around mixing it with other intravenous drugs all deserve a closer look.

What Makes Up the Combination

The “ceftazidime” half is a third-generation cephalosporin that has been in clinical use since the 1980s. It belongs to the beta-lactam family of antibiotics, meaning its core structure includes a beta-lactam ring that is essential to how it kills bacteria. Ceftazidime on its own is effective against many gram-negative organisms, but it can be broken down by beta-lactamase enzymes that resistant bacteria produce. That vulnerability is what made a partner molecule necessary.

Avibactam is a semi-synthetic, non-beta-lactam beta-lactamase inhibitor. Unlike older inhibitors such as clavulanic acid and tazobactam, which are themselves beta-lactam molecules, avibactam has a different chemical scaffold: a diazabicyclooctane (DBO). It blocks Ambler class A, class C, and some class D serine beta-lactamases, covering a broad range of the enzymes that commonly destroy cephalosporins and carbapenems.¹ The two drugs are combined in a fixed 4:1 ratio by weight, and both have a half-life of roughly two hours in healthy adults, which makes them a natural fit for co-administration on the same dosing schedule.²

How Ceftazidime Kills Bacteria

Ceftazidime works by binding to penicillin-binding proteins (PBPs) on the bacterial cell wall. In gram-negative species like Escherichia coli and Pseudomonas aeruginosa, its primary target is PBP-3, which is involved in cell division. When ceftazidime latches onto PBP-3, the bacterium can no longer divide properly and instead forms long, thread-like filaments. At slightly higher concentrations, still achievable with standard dosing, it also hits PBP-1a and PBP-1b, proteins responsible for cell elongation. Blocking those causes the cell wall to weaken rapidly, leading to lysis and death.³ Ceftazidime also penetrates the outer membrane of gram-negative bacteria well, which is part of the reason it has historically been a go-to for Pseudomonas infections.

How Avibactam Protects the Antibiotic

Avibactam’s job is to neutralize the beta-lactamase enzymes that would otherwise chew up ceftazidime before it reaches its PBP targets. It does this through a mechanism that is genuinely unusual among beta-lactamase inhibitors: it forms a covalent bond with the enzyme’s active site, blocking it, but the bond is slowly reversible. When avibactam eventually detaches, it comes off intact rather than being destroyed by hydrolysis. That means a single avibactam molecule can, in principle, go on to inhibit another beta-lactamase molecule.⁴ This recyclability sets avibactam apart from the older inhibitors, which are consumed in the reaction they carry out.

Structural studies have shown how avibactam fits into the binding pockets of different beta-lactamase classes, including class C enzymes (AmpC-type) produced by organisms like P. aeruginosa, revealing differences in how it blocks class A versus class C enzymes at the molecular level.⁵ These structural details have guided efforts to predict which beta-lactamase variants avibactam can still handle and which might escape its grip.

What It Covers and Where It Falls Short

In a large U.S. surveillance study of more than 44,000 gram-negative isolates collected between 2013 and 2016, ceftazidime-avibactam inhibited over 99.9% of all Enterobacteriaceae at the susceptible breakpoint, including about 97.5% of carbapenem-resistant strains. Against P. aeruginosa, roughly 97% of all isolates were susceptible, and among multidrug-resistant Pseudomonas, susceptibility was about 87%.⁶ Those numbers made the combination a game-changer for infections that previously had few treatment options.

The major blind spot is metallo-beta-lactamases (MBLs), the class B enzymes. Avibactam is a serine beta-lactamase inhibitor; it has no meaningful activity against MBLs, which use a zinc ion at their active site instead of a serine residue. In one study, ceftazidime-avibactam was effective against about 88% of class A carbapenemase producers but only about 16% of MBL producers.⁷ Since MBL-producing organisms (those carrying NDM, VIM, or IMP genes) are increasingly common in parts of Asia, Southern Europe, and Latin America, this gap has real clinical consequences.

Closing the MBL Gap with Aztreonam

Aztreonam is a monobactam antibiotic that is inherently stable against MBLs, but it can be broken down by the serine beta-lactamases that many MBL-producing organisms carry alongside their metallo-enzymes. That creates a logical pairing: aztreonam survives the MBL, and avibactam (provided by ceftazidime-avibactam) protects aztreonam from the serine enzymes. In laboratory testing, the combination of aztreonam with ceftazidime-avibactam was synergistic against all Enterobacteriaceae isolates that produced MBLs.⁸ This combination has moved quickly into clinical practice for MBL-positive infections, and a fixed ceftazidime-avibactam-plus-aztreonam product is in development. A Chinese study of carbapenem-resistant Enterobacteriaceae found that while about 75% of strains were susceptible to ceftazidime-avibactam alone, 100% were susceptible when aztreonam was added.⁹

Clinical Effectiveness in Approved Indications

Ceftazidime-avibactam is approved for complicated urinary tract infections (cUTI), complicated intra-abdominal infections (cIAI, used with metronidazole), and hospital-acquired or ventilator-associated pneumonia (HAP/VAP). Pooled data from its Phase 3 trials showed clinical cure rates of about 88% across all indications combined, matching comparator antibiotics. Cure rates were highest for urinary tract infections (around 91%) and lowest for pneumonia (around 80%), which is typical for the severity gradient across those infection types.¹⁰

A systematic review and meta-analysis concluded that ceftazidime-avibactam is clinically as effective as carbapenems for these indications and may even outperform carbapenems in terms of microbiological eradication in urinary tract infections. The same analysis flagged that serious adverse events were slightly more common with ceftazidime-avibactam, warranting ongoing safety monitoring.¹¹

Advantages over Colistin for Resistant Infections

Before ceftazidime-avibactam arrived, colistin (polymyxin E) was often the only option for carbapenem-resistant infections. Colistin works, but it carries a high risk of kidney damage. Head-to-head comparisons have consistently favored ceftazidime-avibactam. In a multicenter cohort study of carbapenem-resistant Enterobacteriaceae bacteremia and other infections, clinical cure was significantly higher with ceftazidime-avibactam (71% vs. 52%), and acute kidney injury was much less common (15% vs. 33%).¹²

A meta-analysis across nine studies involving over 750 patients with carbapenem-resistant Enterobacteriaceae infections found that ceftazidime-avibactam roughly halved 30-day mortality compared to polymyxins and significantly reduced kidney toxicity.¹³ Similar patterns appeared in a study focused specifically on multidrug-resistant P. aeruginosa, where clinical cure with ceftazidime-avibactam was 67% versus 50% with colistin, and kidney injury rates were again substantially lower.¹⁴ These findings have shifted treatment guidelines to favor ceftazidime-avibactam as first-line therapy for KPC-producing and OXA-48-producing infections whenever susceptibility testing confirms activity.

How Resistance Develops

Bacteria are not standing still. Resistance to ceftazidime-avibactam has already been documented, and it arises through several routes. The most well-characterized involves mutations in KPC genes. KPC (Klebsiella pneumoniae carbapenemase) is normally a class A enzyme that avibactam handles well. But under the selective pressure of ceftazidime-avibactam treatment, point mutations in the KPC gene can produce enzyme variants with increased affinity for ceftazidime and slightly reduced sensitivity to avibactam, enough to push the bacterium above the resistance threshold. In laboratory experiments, researchers identified 16 KPC-2 variants and 10 KPC-3 variants that conferred ceftazidime-avibactam resistance.¹⁵

There is a silver lining to this mutation pathway. The same KPC variants that gain the ability to resist ceftazidime-avibactam tend to lose some of their carbapenemase activity. In other words, the trade-off for ceftazidime-avibactam resistance is often renewed susceptibility to carbapenems and other cephalosporins. Clinicians have exploited this collateral sensitivity by switching back to meropenem after ceftazidime-avibactam resistance emerges, though this requires careful susceptibility testing. Clinical studies confirm that KPC mutations are the dominant mechanism behind treatment-emergent resistance. In one study of in vitro simulations designed to mimic in vivo conditions, four KPC-producing K. pneumoniae isolates were treated with ceftazidime-avibactam; three of the four developed KPC-2 variants and became resistant, while the fourth cleared without mutation.¹⁶

In P. aeruginosa, resistance mechanisms are different and arguably harder to manage. Efflux pumps, particularly MexAB-OprM, can actively pump avibactam out of the cell before it reaches its target. Overproduction of AmpC cephalosporinase and loss of the OprD porin (which reduces drug entry) can compound the problem. A study in cystic fibrosis patients showed that these mechanisms working together raised ceftazidime-avibactam MICs to resistant levels.¹⁷ An observational study found that treatment-emergent resistance among patients receiving ceftazidime-avibactam for multidrug-resistant P. aeruginosa was 50% when used as monotherapy, compared with just 6% for ceftolozane-tazobactam monotherapy, a striking difference that has sparked debate about the best regimen for Pseudomonas.¹⁸

Safety Profile and the Renal Impairment Question

Pooled safety data from Phase 2 and Phase 3 trials show a side-effect profile broadly similar to other intravenous cephalosporins. The most common adverse events were diarrhea, nausea, headache, vomiting, and fever. About 11% of patients on ceftazidime-avibactam experienced a drug-related adverse event, compared with about 10% on comparators. Diarrhea was slightly more frequent with ceftazidime-avibactam, especially in patients with intra-abdominal infections (about 7% vs. 4%). Clostridioides difficile-associated diarrhea was uncommon but did occur in a small number of patients across both groups. Liver enzyme elevations were reported at similar rates in treated and comparator groups.¹⁹

The concern that deserves special attention is neurotoxicity in patients with impaired kidney function. Both ceftazidime and avibactam are cleared primarily by the kidneys, so renal impairment leads to drug accumulation. A case report described a 78-year-old woman with acute kidney injury who developed seizures several days into ceftazidime-avibactam treatment; her neurological symptoms resolved completely after the drug was stopped.²⁰ Dose adjustment is required for patients with moderate or severe renal impairment. For patients on continuous renal replacement therapy (CRRT), the standard dose of 2.5 grams every 8 hours may actually cause excessive drug exposure, and researchers have called for revised dosing guidance in that specific setting.²¹

Mixing It with Other IV Drugs

In the ICU, patients often receive several intravenous medications through the same line at the same time (Y-site administration), so physical compatibility matters. Ceftazidime-avibactam has been tested for Y-site compatibility with a range of commonly co-administered IV antimicrobials, including tigecycline, metronidazole, meropenem, imipenem-cilastatin, fosfomycin, aztreonam, and vancomycin. No evidence of incompatibility was found with any of these in simulated Y-site experiments.²² Dedicated compatibility testing of the aztreonam combination, which clinicians use frequently for MBL-producing infections, showed no particulate matter, color changes, turbidity, or pH shifts through 12 hours of observation.²³

A wrinkle worth noting: when ceftazidime-avibactam and vancomycin are mixed in dextrose 5% as an admixture (rather than Y-site), compatibility depends on concentration. At low ceftazidime-avibactam concentrations (8 mg/mL), the admixture was incompatible with vancomycin at 5 mg/mL. At higher ceftazidime-avibactam concentrations (20 or 40 mg/mL), more vancomycin could be accommodated without visible incompatibility.²⁴ The practical takeaway for pharmacy teams is that Y-site co-administration with vancomycin is generally fine, but direct mixing into the same IV bag requires attention to concentration ratios.

Use in Children

Pediatric dosing has been established for patients from three months of age upward, based on pharmacokinetic modeling that targeted drug exposures comparable to those achieved in adults. Children aged six months to 18 years receive weight-based dosing (up to a cap equivalent to the adult dose), while younger infants aged three to six months receive a slightly lower per-kilogram dose, all given as a two-hour infusion every eight hours.²⁵ A Phase 2a trial in neonates and infants under three months found that adjusted doses produced plasma exposures similar to those seen in older children. The safety profile in this very young group was described as expected for the clinical setting, with no deaths or serious adverse events attributed to the drug.²⁶

A systematic review and meta-analysis of pediatric studies found that clinical and microbiological cure exceeded 80% across study designs, with no deaths reported in randomized trials. Observational studies, which tend to capture sicker children with fewer treatment options, reported about 8% mortality.²⁷ Pediatric use remains most common for carbapenem-resistant infections where alternatives are limited.

Getting the Lab Testing Right

Accurately measuring whether a given bacterial isolate is susceptible to ceftazidime-avibactam is harder than it sounds. Automated susceptibility testing systems, the workhorses of most hospital microbiology labs, have not always included panels for this combination. When labs use manual methods, accuracy varies. One study comparing disk diffusion and gradient diffusion (Etest) against the reference method (broth microdilution) found that disk diffusion misclassified 28% of susceptible carbapenem-resistant Enterobacteriaceae isolates as resistant. Gradient diffusion, by contrast, agreed with the reference method 96% of the time.²⁸ A more recent evaluation confirmed that gradient diffusion performs well against both carbapenem-resistant K. pneumoniae (99.1% categorical agreement) and carbapenem-resistant P. aeruginosa (94.1%).²⁹

This matters because a false “resistant” result could steer a clinician away from an effective drug and toward something more toxic. Until labs have validated their methods against the reference standard at their own institution, results should be interpreted with caution, particularly when disk diffusion is the only option available.

Cost and Access Considerations

Ceftazidime-avibactam is expensive. A cost-effectiveness analysis modeling its use for carbapenem-resistant Enterobacteriaceae bacteremia and pneumonia estimated a daily drug cost of about $926 and an incremental cost-effectiveness ratio of roughly $95,000 per quality-adjusted life year (QALY) gained compared to colistin. At the commonly used willingness-to-pay threshold of $100,000 per QALY, ceftazidime-avibactam was the preferred strategy in about 59% of simulations; at $150,000 per QALY, it was preferred in 99%.³⁰ The cost argument is strengthened by the kidney damage colistin frequently causes, since managing acute kidney injury and dialysis adds substantial expense of its own. Still, the per-dose price limits access in lower-resource settings where carbapenem-resistant infections are often most prevalent, a tension that global health advocates have flagged but that has not yet been resolved.

Pharmacokinetics in Critically Ill Patients

Critically ill patients are not pharmacokinetically predictable. Organ dysfunction, fluid shifts, augmented renal clearance in sepsis, and extracorporeal circuits all alter how drugs behave. In one case study of a patient on continuous venovenous hemofiltration, ceftazidime’s half-life extended to about six hours (roughly three times normal), and plasma concentrations remained above the target MIC for the full dosing interval, suggesting adequate coverage but also the potential for accumulation.³¹ Pharmacodynamic modeling in critically ill patients has used Monte Carlo simulations to evaluate the probability that standard dosing achieves therapeutic drug levels, and the results suggest that the standard regimen works for most patients but can fall short or overshoot depending on renal function.³² Therapeutic drug monitoring, while not yet routine for this combination, is being explored in ICU settings to fine-tune dosing for individual patients.